Journal
ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING
Volume 14, Issue 1, Pages -Publisher
WILEY
DOI: 10.1002/dad2.12339
Keywords
Alzheimer's disease; biomarker; caregiver; ethics; law; preclinical
Categories
Funding
- National Institute on Aging [R03AG062975, R01AG054059, R01AG021155, R01AG02716, K01-AG064123]
Ask authors/readers for more resources
This article explores the broader social implications of disclosing Alzheimer's disease biomarkers and identifies challenges and preliminary solutions.
Disclosure of Alzheimer's disease (AD) biomarkers to cognitively unimpaired adults are currently conducted only in research settings. Yet, US Food and Drug Administration approval of a disease-modifying treatment for symptomatic individuals, improved understanding of the preclinical phase of disease, and advancements toward more accessible biomarker tests suggest such disclosure will increase in frequency, eventually becoming routine in clinical practice. The changing landscape in AD research to focus on biomarkers has generated debate on the validity and clinical utility of disclosure to cognitively unimpaired adults. This article explores the broader social implications of more widespread AD biomarker disclosure-that is, of individuals learning their risk for developing dementia caused by AD. We identify 10 challenges and offer preliminary solutions. As the field continues to evolve, it is essential to anticipate and address these broader ethical, legal, and social implications of disclosure.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available